{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/giant-cell-arteritis/diagnosis/suspecting-giant-cell-arteritis/","result":{"pageContext":{"chapter":{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis","depth":2,"htmlHeader":"<!-- begin field 5923b2bc-8efa-4e6c-938c-b6304199b746 --><h2>When should I suspect giant cell arteritis?</h2><!-- end field 5923b2bc-8efa-4e6c-938c-b6304199b746 -->","summary":"","htmlStringContent":"<!-- begin item 50a7de29-4981-4977-b4d4-07b8f1f62abb --><!-- begin field eb8827ac-ab32-4fab-ad0b-b891a6a0608f --><ul><li class=\"MsoNormal\"><strong>Many early symptoms are non-specific but giant cell arteritis (GCA) should be suspected if the person is aged 50 years or older and presents with at least one of:</strong><ul><li class=\"MsoNormal\"><strong>New-onset headache:</strong><ul><li class=\"MsoNormal\">Headache is the most common symptom (occurring in about two thirds of people with GCA) but may not always be present.</li><li class=\"MsoNormal\">The headache is usually temporal but location may vary (for example the person may present with more generalized, occipital, or parietal pain).</li></ul></li><li class=\"MsoNormal\"><strong>A temporal artery abnormality:</strong><ul><li class=\"MsoNormal\">Temporal artery abnormality such as tenderness, thickening, or nodularity is present in up to 30% of people with GCA.</li><li class=\"MsoNormal\">Occasionally the overlying skin is red, and pulsation may be reduced or absent.</li></ul></li></ul></li><li class=\"MsoNormal\"><strong>Other symptoms and signs suggestive of giant cell arteritis include:</strong><ul><li><strong>Visual disturbances such as loss of vision, diplopia, or changes to colour vision.</strong><ul><li>Up to 30% of people with GCA develop visual loss that may be transient or permanent — in people with unilateral visual loss there is a 20–50% chance of the other eye also being affected.</li><li>Double vision, visual field defects, or changes to colour vision may occur.</li><li>Fundoscopic findings are not specific to GCA but may include pallor and oedema of the optic disc, and 'cotton-wool' patches and small haemorrhages in the retina — these features are usually seen following loss of vision.</li></ul></li><li><strong>Scalp tenderness.</strong><ul><li>Occurs in about 50% of people, in particular over the temporal and occipital arteries for example on brushing hair.</li><li>Scalp necrosis may occur but is less common.</li></ul></li><li><strong>Intermittent jaw claudication.</strong><ul><li>Occurs in nearly half of people with GCA, causing pain in the jaw muscles (typically over the masseter after minutes of chewing).</li><li>Occasionally, intermittent claudication affects the tongue, or the muscles involved in swallowing.</li></ul></li><li><strong>Systemic features.</strong><ul><li>Systemic features such as fever (usually low grade), fatigue, anorexia, weight loss, and depression are often present.</li></ul></li><li><strong>Features of polymyalgia rheumatic (PMR).</strong><ul><li>Features of PMR (such as proximal muscle pain, stiffness, and tenderness) are present in about 40% of people with GCA.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polymyalgia-rheumatica/\">Polymyalgia rheumatica</a>.</li></ul></li><li><strong>Neurological features</strong> — occur in about 30% of people and include:<ul><li>Mononeuropathy or polyneuropathy of the arms or legs.</li><li>Transient ischaemic attack or stroke in the distribution of the carotid or vertebrobasilar arteries (less common).</li><li>Upper cranial nerve palsies.</li></ul></li><li><strong>Respiratory or ear, nose, and throat symptoms.</strong><ul><li>GCA may occasionally present with audio vestibular symptoms or respiratory symptoms such as cough, sore throat, and hoarseness.</li></ul></li><li><strong>Features associated with extra-cranial large vessel involvement such as:</strong><ul><li>Bruits (for example the carotid artery).</li><li>Decreased arterial pulsation/blood pressure difference between arms.</li><li>Intermittent arm/limb claudication (due to stenosis).</li><li>Back or chest pain (due to aortitis or aortic dissection).</li></ul></li></ul></li><li><strong>As clinical features are not specific for GCA other possible causes of symptoms should be considered.</strong><ul><li>Features suggestive of another cause include neurological deficits, severe systemic features, and localized ear, nose, and throat signs.</li></ul></li></ul><!-- end field eb8827ac-ab32-4fab-ad0b-b891a6a0608f --><!-- end item 50a7de29-4981-4977-b4d4-07b8f1f62abb -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","lastRevised":"Last revised in September 2020","chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","fullItemName":"Management","slug":"management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"1b8c66e3-7400-5cdb-b28c-c162c24b084f","slug":"basis-for-recommendation-1c3","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 3b7f097e-135e-4027-93f3-db84fc3d1d91 --><h3>Basis for recommendation</h3><!-- end field 3b7f097e-135e-4027-93f3-db84fc3d1d91 -->","summary":null,"htmlStringContent":"<!-- begin item 1c38c8de-62d4-470d-95ec-c89a16307281 --><!-- begin field e4aaa8c4-bc2c-4939-9140-bb8ac8692ec2 --><p class=\"MsoNormal\">These recommendations are based on the clinical guidelines <em>Management of descending thoracic aorta diseases: clinical practice guidelines of the European Society for Vascular Surgery (ESVS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Riambau, 2017</a>], <em>Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>], <em>British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>], <em>European Headache Federation recommendations for neurologists managing giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>], the American College of Rheumatology classification criteria for giant cell arteritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hunder&nbsp;1990</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Imran, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Bienvenu, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hoffman, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Dejaco, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Koster, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Vodopivec, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</p><h4 class=\"MsoNormal\">Age, headache, and temporal artery abnormality</h4><ul><li class=\"MsoNormal\">The British Society for Rheumatology guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] states that headache, scalp tenderness, jaw claudication, visual loss, and stroke are all cranial manifestations of giant cell arteritis (GCA). Inflammation of the aorta and/or its proximal branches is also common in GCA and may be asymptomatic or present with non-specific systemic symptoms, such as fever or weight loss.</li><li>The National Institute of Health and Care Excellence guideline on <em>Suspected neurological conditions: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">NICE, 2019</a>] recommends that temporal arteritis is always considered as a possible cause of facial pain and headache in older people. Other symptoms mentioned as suggestive of temporal arteritis are scalp tenderness or jaw claudication.</li><li>The American College of Rheumatology classification criteria for giant cell arteritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hunder&nbsp;1990</a>] includes age at disease onset of 50 years or older, new-onset headache, and temporal artery abnormality. Other criteria include elevated erythrocyte sedimentation rate (ESR) of 50 mm/hour or more and an abnormal artery biopsy.</li></ul><h4 class=\"MsoNormal\">Visual symptoms</h4><ul><li class=\"MsoNormal\">The information on visual symptoms associated with GCA is based on expert opinion in clinical guidelines and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hoffman, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Dejaco, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Koster, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Vodopivec, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].</li><li>Visual loss (which is usually painless) occurs owing to involvement of the ophthalmic artery and its branches. It may rarely result from occipital lobe infarction that presents with homonymous hemianopia. Visual hallucinations and diplopia are less common. All visual symptoms require urgent ophthalmological assessment and treatment with high dose glucocorticoids to reduce the risk of permanent visual loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Vodopivec, 2018</a>].</li></ul><h4 class=\"MsoNormal\">Systemic features</h4><ul><li class=\"MsoNormal\">Expert opinion in clinical guidelines and review articles is that systemic features are common in people with GCA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li class=\"MsoNormal\">Systemic symptoms may be the dominant clinical feature in about 15% of people with GCA at presentation, and in 20% of cases at time of relapse [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Dejaco, 2017</a>].</li></ul><h4 class=\"MsoNormal\">Consider the differential diagnosis</h4><ul><li class=\"MsoNormal\">This recommendation is based on clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>] — no clinical features are specific to GCA and diagnosis can be challenging.</li><li>The most common presenting symptom of GCA is headache but as GCA is relatively rare, other causes of headache are much more common in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</li></ul><!-- end field e4aaa8c4-bc2c-4939-9140-bb8ac8692ec2 --><!-- end item 1c38c8de-62d4-470d-95ec-c89a16307281 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}